1. Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives
   Masaki Hanibuchi et al, 2024, The Journal of Medical Investigation CrossRef
2. Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis
   Xinru Chen et al, 2020, Journal for ImmunoTherapy of Cancer CrossRef
3. Bevacizumab/carboplatin/paclitaxel
   , 2014, Reactions Weekly CrossRef
4. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia
   Takashi Ogura et al, 2019, Respiratory Investigation CrossRef
5. Avastin® in combination with gemcitabine and cisplatin significantly inhibits tumor angiogenesis and increases the survival rate of human A549 tumor-bearing mice
   YING LIU et al, 2015, Experimental and Therapeutic Medicine CrossRef
6. Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat
   Yan-Yan Zhao et al, 2016, PLOS ONE CrossRef
7. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias
   Tetsuo Fujita et al, 2018, Internal Medicine CrossRef
8. Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer
   Yasuhito Sekimoto et al, 2016, Respirology Case Reports CrossRef
9. Phase II study of carboplatin plus weekly paclitaxel with bevacizumab for non-squamous, non-small cell lung cancer with idiopathic interstitial pneumonia (Hanshin Cancer Group IP002)
   Nobuyuki Katakami et al, 2024, Japanese Journal of Clinical Oncology CrossRef